Trump Threatens Aircraft Tariffs as U.S.-Canada Jet Certification Dispute Escalates 
NVIDIA, Microsoft, and Amazon Eye Massive OpenAI Investment Amid $100B Funding Push 
Asian Currencies Slip as Dollar Rebounds Ahead of Fed Rate Decision 
Tesla Q4 Earnings Beat Expectations as Company Accelerates Shift Toward AI and Robotics 
Asia Stocks Pause as Tech Earnings, Fed Signals, and Dollar Weakness Drive Markets 
Google Disrupts Major Residential Proxy Network IPIDEA 
MAS Holds Monetary Policy Steady as Strong Growth Raises Inflation Risks 
Trump Threatens 50% Tariff on Canadian Aircraft Amid Escalating U.S.-Canada Trade Dispute 
Chinalco and Rio Tinto Acquire Controlling Stake in Brazil’s CBA for $903 Million 
The Maire - EuroChem Case: Three Lessons for Global Business 
China to Boost Brazilian Soybean Imports in Early 2026 Amid Price Advantage 
Amazon Stock Dips as Reports Link Company to Potential $50B OpenAI Investment 
Elon Musk’s SpaceX Explores Merger Options With Tesla or xAI, Reports Say 
Wall Street Slips as Tech Stocks Slide on AI Spending Fears and Earnings Concerns 
Advantest Shares Hit Record High on Strong AI-Driven Earnings and Nvidia Demand 
Puma’s Historic Rivalry With Adidas Enters a New Era as Anta Deal Signals Turnaround Push 
Asian Currencies Trade Flat as Dollar Retreats After Fed Decision 
Abbott Nutrition said last weekend that it had reopened its Sturgis, Michigan plant to resume the production of baby formula. The company hopes that the nationwide shortage of milk will be addressed once it begins the normal production once again.
Abbott Nutrition was able to open its production facility in Michigan after the U.S. Food and Drug Administration (USFDA) had given it the go-ahead to do so. The permit was granted by the agency after the company met the initial requirements as part of a May 16 consent decree.
According to CNBC, Abbott Nutrition will now restart the production of its EleCare baby formula that has been formulated for children who have difficulties digesting other products. The company will also manufacture its other specialty milk and metabolic formulas for infants.
As the company is now able to begin production again, it is hoping to release the first batch of EleCare milk products by June 20. Currently, Abbott is still working to comply with the guidelines set for the resumption of production for its Similac milk line and other infant formulas.
“We understand the urgent need for formula and our top priority is getting high-quality, safe formula into the hands of families across America,” Abbott’s spokesman said in a statement. “We will ramp production as quickly as we can while meeting all requirements.“
It was noted that the issue with the supply of baby formula began in the early stage of the COVID-19 pandemic. However, the situation got worse when Abbott Nutrition’s production facility in Michigan was ordered to close due to contamination. The plant was shut down in February following reports of illnesses in babies after consuming the company-made milk formulas, and two infants have died.
“The FDA is continuing to work diligently to ensure the safe resumption of production of infant formula at Abbott Nutrition’s Sturgis, Michigan, facility,” the USFDA commented with regards to Abbot’s plant reopening. “The agency expects that the measures and steps it is taking, and the potential for Abbott Nutrition’s Sturgis, Michigan, facility, to safely resume production in the near-term, will mean more and more infant formula is either on the way to or already on store shelves moving forward.”
